- Tocilizumab, sold
under the
brand name
Actemra among others, is an
immunosuppressive drug, used for the
treatment of
rheumatoid arthritis,
systemic juvenile...
-
shipping product on June 30, 2006, the day the
product was approved. 2010:
Actemra (tocilizumab): The
first interleukin-6 (IL-6) receptor-inhibiting monoclonal...
-
launched 2005:
Actemra launched 2007:
Copegus , an antiviral,
Avastin , a
cancer drug, and
Tarceva , a
cancer drug
launched 2011 –
Produced Actemra, a human...
-
available as RoAccutane,
other brand names and
Isotretinoin generics.
Actemra/Ro
Actemra (tocilizumab), for
rheumatoid arthritis.
Actimmune (interferon gamma)...
- inhibitors. The
first approved medication in this class,
tocilizumab (
Actemra), is an
antibody directed against the IL6-receptor. The second, siltuximab...
-
Archived from the
original on
August 14, 2019.
Retrieved April 4, 2022. "Ro
Actemra EPAR".
European Medicines Agency.
January 16, 2009.
Archived from the original...
- arthritis; however, the
antibody lacked a dose-response effect.
Tocilizumab (
Actemra) an anti-IL-6
receptor mAb Anti-IL-6,
other anti-interleukin-6
agents Handbook...
-
behalf of
other organisations. Four of these,
Tysabri (Biogen Idec/Elan),
Actemra (Hoffmann-La Roche/Chugai),
Entyvio (Millenium Pharma/Takeda) and Keytruda...
- from the
original on 21
September 2021.
Retrieved 21
September 2021. "Ro
Actemra EPAR".
European Medicines Agency. 17
September 2018.
Archived from the...
- 2020. "Roche
provides an
update on the
phase III
COVACTA trial of
Actemra/Ro
Actemra in
hospitalised patients with
severe COVID-19 ****ociated pneumonia"...
